Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Otakanomori Hospital
Homepage:
otakanomori-hp.com
Alternate name:
医療法人社団誠高会おおたかの森病院
ROR:
03ygpv007
OpenAlex ID:
I4405256241
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
2018
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Liver Cancer
·
264
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
2019
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Cancer Medicine
·
159
PDF
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
2017
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Digestive Diseases
·
159
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection
2017
·
Kentaro Matsuura
, Hiromi Sawai
, et al.
·
Gastroenterology
·
155
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
2022
·
Andrea Casadei-Gardini
, Margherita Rimini
, et al.
·
European Journal of Cancer
·
142
PDF
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
2022
·
M. Rimini
, L. Rimassa
, et al.
·
ESMO Open
·
132
PDF
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
2018
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Cancer Medicine
·
130
PDF
Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics
2020
·
Kenichi Sakakura
, Yoshiaki Ito
, et al.
·
Cardiovascular Intervention and Therapeutics
·
102
PDF
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
2018
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Hepatology Research
·
95
PDF
A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion
2019
·
Hiroyuki Tanaka
, Etsuo Tsuchikane
, et al.
·
Journal of the American College of Cardiology
·
94
PDF
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
2020
·
Toshifumi Tada
, Takashi Kumada
, et al.
·
Liver International
·
87
PDF
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
2022
·
Takeshi Hatanaka
, Satoru Kakizaki
, et al.
·
Hepatology International
·
86
PDF
Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics: update 2023
2023
·
Kenichi Sakakura
, Yoshiaki Ito
, et al.
·
Cardiovascular Intervention and Therapeutics
·
85
PDF
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
2022
·
Takaaki Tanaka
, Atsushi Hiraoka
, et al.
·
Hepatology Research
·
83
PDF
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
2019
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Oncology
·
82
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
2020
·
Kazuya Kariyama
, Kazuhiro Nouso
, et al.
·
Liver Cancer
·
73
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
2023
·
Mara Persano
, Margherita Rimini
, et al.
·
European Journal of Cancer
·
65
PDF
Role of 0D peripheral vasculature model in fluid–structure interaction modeling of aneurysms
2009
·
Ryo Torii
, Marie Oshima
, et al.
·
Computational Mechanics
·
65
Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis
2022
·
Toshifumi Tada
, Takashi Kumada
, et al.
·
European Journal of Gastroenterology & Hepatology
·
62
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching
2019
·
Toshifumi Tada
, Takashi Kumada
, et al.
·
Hepatology Research
·
57
Influencing factors in image‐based fluid–structure interaction computation of cerebral aneurysms
2010
·
Ryo Torii
, Marie Oshima
, et al.
·
International Journal for Numerical Methods in Fluids
·
57
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan
2017
·
Goki Suda
, Norihiro Furusyo
, et al.
·
Journal of Gastroenterology
·
56
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
2021
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Hepatology Research
·
52
PDF
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
2019
·
Atsushi Hiraoka
, Takashi Kumada
, et al.
·
Oncology
·
52
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
2021
·
Margherita Rimini
, Shigeo Shimose
, et al.
·
Hepatology Research
·
51
PDF
Show more works
View as search
Works count:
163
Citation count:
4,744
Year
Topic
Type
